A Study to Assess the Pharmacokinetics and Ability for Pediatric Patients with Type 2 Diabetes to Swallow MK-0431A XR Tablets - Trial 2020-003731-22

Name: Clinical Trial 2020-003731-22
Creator: Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.
Keywords: Type 2 Diabetes Mellitus, clinical trial

Access comprehensive clinical trial information for 2020-003731-22 through Pure Global AI's free database. This phase not specified trial is sponsored by Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc. and is currently status unknown. The study focuses on Type 2 Diabetes Mellitus.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to EU Clinical Trials Register data, helping medical device and pharmaceutical companies navigate clinical research efficiently.

Free Database

840K+ Trials

2020-003731-22

Trial Details

EU Clinical Trials Register • 2020-003731-22

DJ Fang

MedTech Regulatory Expert

Need help with 30+ markets registration?

Pricing

A Study to Assess the Pharmacokinetics and Ability for Pediatric Patients with Type 2 Diabetes to Swallow MK-0431A XR Tablets

Study Focus

Disease/Condition

Type 2 Diabetes Mellitus

Sponsor & Location

Primary Sponsor

Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.

Timeline & Enrollment

Phase

N/A

Start Date

N/A

End Date

N/A

Primary Outcome

• Mental or legal incapacitation

ICD-10 Classifications

Type 2 diabetes mellitus

Type 2 diabetes mellitus with unspecified complications

Type 2 diabetes mellitus with other specified complications

Type 2 diabetes mellitus without complications

Type 2 diabetes mellitus with multiple complications

Data Source

Registry

EU Clinical Trials Register

Trial ID

2020-003731-22

Type

Non-Device Trial